New medicines race incoming patent cliffs and price cuts
- The Growth Portfolio includes eight products generating over $1 billion annually, driven by Cobenfy and Qvantig.
- The FDA granted accelerated approval to Symvexis in the third quarter of 2026, establishing a new class of multiple myeloma treatments.
- Older blockbuster drugs face immediate threats, with Eliquis losing European exclusivity in late 2026.
- Key pipeline trial readouts for Milvexian and Cobenfy are scheduled for early 2027, which will test future growth.
- The company aims to save $2 billion by 2027 by using artificial intelligence to speed up drug discovery.
A hard handoff to newer drugs
Bristol-Myers Squibb is in a transition. Older blockbusters are losing protection, while newer drugs are trying to fill the hole. In the third quarter of 2026, management noted the Growth Portfolio now has eight blockbuster products.
The bull case points to commercial momentum and pipeline wins. Opdivo Qvantig reached a $1.3 billion annual run rate, helping defend market share against future biosimilars. The FDA also granted accelerated approval to Symvexis, a new multiple myeloma treatment.
The bear case highlights shrinking profit margins and upcoming revenue cliffs. Eliquis will lose European exclusivity in late 2026 ahead of a massive global drop expected in 2027. Orencia will face both Medicare price negotiations and a new biosimilar rival in 2028.
The next test is simple to state but hard to pass. The company must prove its new products can grow fast enough to beat lower prices, generic rivals, and late decade patent cliffs.
Patents turn science into sales
Bristol-Myers Squibb makes money by selling prescription drugs that are protected by patents. These drugs treat serious diseases in oncology, hematology, immunology, cardiovascular disease, and neuroscience.
The model can be very profitable while patents last. It breaks quickly when a top drug loses exclusivity, which means cheaper generic or biosimilar versions can enter the market. That is already happening with Revlimid and Pomalyst.
Management is trying to make the company leaner at the same time. A strategic productivity initiative targets $2 billion in cost savings by the end of 2027. The company is using shorter research cycle times and commercial efficiencies to reach that goal.
The company also partners for growth when it needs to. BMY recently secured artificial intelligence agreements with Anthropic and NVIDIA to speed up drug discovery and improve decision making.
Where the drug mix is shifting
Eliquis
Eliquis is a major blood thinner and faces a loss of exclusivity in Europe in late 2026, followed by a steep global decline expected in 2027.
Opdivo and Opdivo Qvantig
Opdivo is a large cancer franchise. BMY is shifting patients toward the under the skin version called Qvantig, which has reached a $1.3 billion run rate.
Cobenfy
Cobenfy is a key neuroscience launch for schizophrenia. A major focus is educating doctors to increase patient doses for better results.
Symvexis
Symvexis received accelerated FDA approval in late 2026 as a new pill option for multiple myeloma.
Camzyos
Camzyos treats a heart condition that blocks blood flow. It recently expanded to pediatric patients and continues to grow quickly.
Reblozyl
Reblozyl treats anemia tied to certain blood disorders. It generated $750 million in the third quarter of 2026.
Revlimid and Pomalyst
These legacy blood cancer drugs are under heavy generic pressure. Generic erosion continues to drag down overall revenue for the older portfolio.
Mostly a U.S. drug company
The mix uses early 2026 revenue by geography: $7.8 billion from the United States and $3.4 billion from international markets. U.S. results are heavily exposed to Medicare price pressure.
What could break the bridge
Eliquis price and patent reset
High impact · High oddsEliquis is a cash cow right now. However, the drug faces European exclusivity loss in late 2026 and a massive revenue step down in 2027 due to pricing changes.
Pipeline readout delays
High impact · Medium oddsCritical trial results for Milvexian and Cobenfy shifted to early 2027. Bad data would shrink the future growth bridge and limit the pipeline.
Orencia double threat
High impact · High oddsOrencia will face federal price negotiations beginning in 2028. The company also allowed a subcutaneous biosimilar to launch in the U.S. around the same time.
Legacy cliff steepens
High impact · High oddsRevlimid fell sharply in 2026 as generic competition widened in the U.S. while Pomalyst is also under pressure. If these decline faster than the Growth Portfolio rises, total revenue will fall.
Opdivo defense may not hold
Medium impact · Medium oddsThe company is pushing conversion to Opdivo Qvantig, reaching 17 percent market share in the U.S. recently. The open question is if Qvantig can protect market share against future biosimilars.
In one breath
Why is Bristol-Myers Squibb under pressure?
Several older drugs are losing exclusivity, which lets cheaper rivals take share. At the same time, U.S. pricing pressure is rising for drugs like Eliquis, Pomalyst, and Orencia.
What is the main bull case for BMY?
The bull case is that newer drugs can outgrow the legacy decline. The Growth Portfolio now includes eight products generating over $1 billion annually.
Why does Eliquis matter so much?
Eliquis is a massive blood thinner franchise that generates billions in revenue. A large revenue drop expected in 2027 is one of the clearest near term risks for the company.
What is Opdivo Qvantig?
Opdivo Qvantig is a version of Opdivo given under the skin instead of by IV infusion. BMY hopes it can make the franchise harder to displace as future competition rises.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Bristol-Myers Squibb Company in Finn's Drug Manufacturers - General industry ranking.

